Prognostic value of high‐sensitive troponin T for predicting cardiovascular events after atrial fibrillation ablation

This study aimed to evaluate the utility of high‐sensitive troponin T (hs‐TnT) for predicting AF recurrence and major adverse cardiovascular events (MACE) after AF ablation.

[1]  M. Uematsu,et al.  An E/e′ ratio on echocardiography predicts the existence of left atrial low-voltage areas and poor outcomes after catheter ablation for atrial fibrillation , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  M. Masuda,et al.  Left atrial low-voltage areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation. , 2018, International journal of cardiology.

[3]  K. Shimada,et al.  High-sensitive cardiac troponin T as a novel predictor for recurrence of atrial fibrillation after radiofrequency catheter ablation , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  N. Gronich,et al.  Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity score-matched analysis. , 2017, Heart rhythm.

[5]  J. Goldberger,et al.  Cryoballoon versus Radiofrequency Catheter Ablation in Atrial Fibrillation: A Meta‐Analysis , 2016, Journal of cardiovascular electrophysiology.

[6]  L. Friberg,et al.  Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. , 2016, European heart journal.

[7]  Guoqiang Zhong,et al.  Efficacy and safety of the second-generation cryoballoons versus radiofrequency ablation for the treatment of paroxysmal atrial fibrillation: a systematic review and meta-analysis , 2016, Journal of Interventional Cardiac Electrophysiology.

[8]  A. Gorst-rasmussen,et al.  Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. , 2015, JAMA.

[9]  L. Fauchier,et al.  Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. , 2015, European heart journal.

[10]  H. May,et al.  The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. , 2015, Heart rhythm.

[11]  J. Healey,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. , 2014, JAMA.

[12]  Nazem Akoum,et al.  Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. , 2014, JAMA.

[13]  D. Atar,et al.  High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. , 2014, Journal of the American College of Cardiology.

[14]  D. Pennell,et al.  Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non‐ischaemic dilated cardiomyopathy , 2013, European journal of heart failure.

[15]  H. Katus,et al.  High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. , 2010, Clinical chemistry.

[16]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[17]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[18]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[19]  R B D'Agostino,et al.  Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.